Spruce Biosciences Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Good afternoon, everyone, and welcome to H.C. Wainwright's 24th Annual Global Investment Conference. I'm Jennifer Sadeghi, an associate at H.C. Wainwright. And I'd like to introduce CFO Samir Gharib of Spruce Biosciences.
Spruce is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders. Samir?
Great. Thank you, Jennifer. It's a pleasure to be here today, and it's a pleasure to provide a summary over Spruce Biosciences. As Jennifer noted, we're a late-stage company focused on the development and commercialization of novel therapies for rare endocrine disorders with significant unmet medical need.
Now, over the course of today's presentation, I do plan to make some forward-looking statements that are based on the beliefs and assumptions of management. I'd refer you to our filings with the SEC for more information around the risks and uncertainties regarding investment
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |